Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD

Article

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

In an interview with CancerNetwork® during the 2022 Tandem Meeting, Alina Markova, MD, dermatologist and director of inpatient consultative dermatology at Memorial Sloan Kettering Cancer Center, discussed the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream (Opselura) in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease (GVHD). She highlights that other topical treatments for the disease, such as steroids, can negatively impact survivors’ quality of life due to adverse effects (AEs) such as bruising and skin thinning. This leaves an unmet need in this patient population.

Transcript:

There are currently no FDA-approved topical therapies for chronic cutaneous [GVHD]. The main topical treatment that is currently used for chronic cutaneous [GVHD] is topical steroids. Topical steroids with long-term use have significant toxicity, [such as] skin thinning and bruising—things that are irreversible and can affect the quality of life of our survivors. Other treatments that are used off label are topical calcineurin inhibitors such as tacrolimus [Protopic], and they have AEs such as burning. Ultimately, both are ineffective and we need other treatments in order to increase [the number of] tools that we have to treat cutaneous involvement of GVHD.

Reference

Markova A, Prockop SE, Dusza S, et al. Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Presented at: 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022. Abstract 390.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content